Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Summit Therapeutics Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.12 (market cap $12.87B), while Summit Therapeutics Inc trades at $17.54 (market cap $13.71B). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF and Summit Therapeutics Inc are close in size by market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 51 Days and Summit Therapeutics Inc for 16 Days on average.
| EMB | SMMT | |
|---|---|---|
Market Cap | $12.87B | $13.71B |
Volume | 14,946,002 | 6,173,057 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $26.38 |
52-Week Low | $90.14 | $12.43 |
Typical Hold Time | 51 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $91.13 with a slight 0.39% daily gain, though technical indicators signal bearish momentum with moving averages and ADX showing sell signals. The stock faces resistance near $91-92 levels while finding support around $90. Recent dividend announcements for H2-2026 provide income appeal, but fundamental metrics remain undisclosed in current data.
The outlook appears cautious given bearish technical signals and limited fundamental visibility. Investment opportunity rests on income generation through scheduled dividends, while risks include technical weakness and potential market volatility from rising bond yields affecting fixed-income alternatives.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
